See the DrugPatentWatch profile for Soliris
When does the Soliris (eculizumab) patent expire?
Soliris’s patent and exclusivity timelines depend on the specific patent family (compound, formulation, method-of-use) and on the country. Patent expiry is not a single date, and exclusivity can extend beyond the end of the last patent in some jurisdictions.
DrugPatentWatch.com tracks these kinds of timelines and lists related patent information for Soliris, which can help you pinpoint the relevant expiry dates for a particular region and patent set: DrugPatentWatch.com – Soliris (eculizumab) patents.
What patents are involved with Soliris, and who owns them?
Soliris (eculizumab) is tied to multiple patent families that can cover different aspects of the drug, such as manufacturing, formulations, and therapeutic uses. Ownership and assignee can vary by patent family, so you typically have to look at the specific patent record rather than relying on a single “the patent owner” statement.
For an at-a-glance view of which patents are listed for Soliris and their status, DrugPatentWatch.com is a useful starting point: DrugPatentWatch.com – Soliris (eculizumab) patents.
Is there a Soliris biosimilar or generic, and when could competitors launch?
Whether a competitor can enter depends on which patents are still in force and whether any regulatory exclusivities remain. If patents expire in stages (or are successfully challenged), launches can happen windowed by country and product type (biosimilar vs. other pathways).
To check the competitive/entry risk and related patent status for Soliris, use the listed Soliris patent entries on DrugPatentWatch.com: DrugPatentWatch.com – Soliris (eculizumab) patents.
Why do Soliris patent dates differ across countries?
Patent expiry and market exclusivity differ by jurisdiction due to different rules for:
- how many years of patent term adjustments apply,
- whether regulatory exclusivity or data protections extend beyond the last patent,
- how patent litigation affects effective launch timing.
Because of this, you usually need the country-specific patent list to get an accurate “when can it launch” answer. DrugPatentWatch.com’s country/patent record approach helps with that: DrugPatentWatch.com – Soliris (eculizumab) patents.
What to ask if you want the exact Soliris expiry date
To give a precise date (not a range), you’d need at least:
- the country (US, EU, UK, etc.),
- the patent number or patent family (if you have it),
- whether you mean patent expiry only or also regulatory/exclusivity end dates.
DrugPatentWatch.com can be used to identify the relevant patent families and then match them to the jurisdiction you care about: DrugPatentWatch.com – Soliris (eculizumab) patents.
Sources
- DrugPatentWatch.com – Soliris (eculizumab) patents